[go: up one dir, main page]

HUP9903942A2 - Nemvizes protikus peptid készítmények - Google Patents

Nemvizes protikus peptid készítmények

Info

Publication number
HUP9903942A2
HUP9903942A2 HU9903942A HUP9903942A HUP9903942A2 HU P9903942 A2 HUP9903942 A2 HU P9903942A2 HU 9903942 A HU9903942 A HU 9903942A HU P9903942 A HUP9903942 A HU P9903942A HU P9903942 A2 HUP9903942 A2 HU P9903942A2
Authority
HU
Hungary
Prior art keywords
peptide compound
preparations
aqueous
aqueous protic
peptide formulations
Prior art date
Application number
HU9903942A
Other languages
English (en)
Inventor
James B. Eckenhoff
Joe Leonard
Steven J. Prestrelski
Cynthia L. Stevenson
Sally A. Tao
Jeremy C. Wright
Original Assignee
Alza Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corporation filed Critical Alza Corporation
Publication of HUP9903942A2 publication Critical patent/HUP9903942A2/hu
Publication of HUP9903942A3 publication Critical patent/HUP9903942A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány tárgyát stabil, nemvizes, peptidvegyületet tartalmazókészítmények képezik, amelyek a) legalább egy peptidvegyületet és b)legalább egy nemvizes prőtikűs őldószert tartalmaznak, amelykészítmények 37 řC hőmérsékleten legalább 3 hónapig stabilak. Akészítményekben a peptidvegyület kőncentrációja legalább 10 tömeg%,előnyösen legalább 30 tömeg%. A készítmények peptidvegyületként LHRH-rőkőn vegyületet, így leűprőlidőt, nafarelint, LHRH-t vagy példáűlgőserelint tartalmaznak. A készítmények előállításáhőz nemvizesprőtikűs őldószerként PG-t, PEG-t vagy glicerint alkalmaznak. Atalálmány szerinti készítmények eredményesen alkalmazhatók többekközött prősztatarák kezelésére. ŕ
HU9903942A 1996-07-03 1997-07-01 Non-aqueous protic peptide formulations HUP9903942A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2112996P 1996-07-03 1996-07-03

Publications (2)

Publication Number Publication Date
HUP9903942A2 true HUP9903942A2 (hu) 2000-04-28
HUP9903942A3 HUP9903942A3 (en) 2000-07-28

Family

ID=21802501

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903942A HUP9903942A3 (en) 1996-07-03 1997-07-01 Non-aqueous protic peptide formulations

Country Status (27)

Country Link
EP (1) EP0909175B1 (hu)
JP (3) JP2001504802A (hu)
CN (1) CN1231256C (hu)
AR (1) AR008060A1 (hu)
AT (1) ATE241997T1 (hu)
AU (1) AU737664B2 (hu)
BR (1) BR9710130A (hu)
CA (1) CA2259403A1 (hu)
CO (1) CO4890854A1 (hu)
CZ (1) CZ433898A3 (hu)
DE (1) DE69722620T2 (hu)
DK (1) DK0909175T3 (hu)
ES (1) ES2201306T3 (hu)
HU (1) HUP9903942A3 (hu)
ID (1) ID19165A (hu)
IL (1) IL127769A (hu)
MY (1) MY121684A (hu)
NO (1) NO323933B1 (hu)
NZ (1) NZ333580A (hu)
PL (1) PL189402B1 (hu)
PT (1) PT909175E (hu)
RO (1) RO119862B1 (hu)
RU (1) RU2203085C2 (hu)
SK (1) SK284490B6 (hu)
TW (1) TW491703B (hu)
WO (1) WO1998000152A1 (hu)
ZA (1) ZA975942B (hu)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2201306T3 (es) * 1996-07-03 2004-03-16 Alza Corporation Formulaciones peptidicas proticas no acuosas.
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004233869B2 (en) * 2003-04-25 2010-08-12 Boston Scientific Scimed, Inc. Solid drug formulation and device for storage and controlled delivery thereof
AU2004290862B2 (en) * 2003-11-20 2010-06-03 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
NZ572003A (en) 2006-05-30 2010-07-30 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator with spiral fluid channel
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
CN106389330A (zh) * 2007-01-19 2017-02-15 哈南亚有限公司 用于递送治疗剂的方法和组合物
AU2013203271B2 (en) * 2007-01-19 2016-05-12 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
JP5658031B2 (ja) 2007-06-22 2015-01-21 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 薄膜凍結による安定したサブミクロンのペプチド又はタンパク質粒子の形成
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CA2730760A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
KR20210043728A (ko) 2008-08-15 2021-04-21 아이언우드 파마슈티컬스, 인코포레이티드 경구 투여를 위한 리나클로타이드-함유 제형
KR20110103961A (ko) 2008-11-16 2011-09-21 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 저점도 고농축 현탁액
US8748573B2 (en) 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
UA108636C2 (xx) 2010-02-17 2015-05-25 Пептид
LT2603232T (lt) 2010-08-11 2020-01-27 Ironwood Pharmaceuticals, Inc. Stabilios linaklotido vaisto formos
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
DK2776055T3 (en) 2011-08-17 2017-03-06 Ironwood Pharmaceuticals Inc TREATMENTS FOR GASTROINTESTINAL DISORDERS
EP2659902A1 (en) * 2012-04-30 2013-11-06 Sun Pharmaceutical Industries Limited Leuprolide injection
US9956287B2 (en) 2013-02-06 2018-05-01 Perosphere Inc. Stable glucagon formulations
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016196851A2 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
IL262802B2 (en) 2016-05-16 2025-04-01 Intarcia Therapeutics Inc Glucagon receptor selective polypeptides and methods of using them
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
EP3372224A1 (en) 2017-03-07 2018-09-12 Alrise Biosystems GmbH New controlled drug delivery system using water miscible solvents for production of drug loaded micro- and nanoparticles
CA3082033A1 (en) 2017-08-24 2019-02-28 Novo Nordisk A\S Glp-1 compositions and uses thereof
BR112022013746A2 (pt) 2020-02-18 2022-10-11 Novo Nordisk As Formulação aquosa de cagrilintida, formulação aquosa de semaglutida, dispositivo médico, e, combinação de dose fixa

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897256A (en) * 1986-11-25 1990-01-30 Abbott Laboratories LHRH analog formulations
ES2061591T3 (es) * 1987-10-15 1994-12-16 Syntex Inc Administracion intranasal de polipeptidos en forma pulverizada.
IT1237197B (it) * 1989-11-16 1993-05-26 Sclavo Spa Formulazioni farmaceutiche anidre e forme di dosaggio per la somministrazione rettale di calcitonina.
DK0661989T3 (da) * 1992-09-21 1998-03-02 Upjohn Co Proteinsammensætninger med vedvarende frigivelse
EP0686045B1 (en) * 1993-02-23 2000-11-15 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
US5955430A (en) * 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
JP3597233B2 (ja) * 1993-10-21 2004-12-02 久光製薬株式会社 経鼻組成物及びそれを含有する経鼻製剤
ES2201306T3 (es) * 1996-07-03 2004-03-16 Alza Corporation Formulaciones peptidicas proticas no acuosas.

Also Published As

Publication number Publication date
JP2008195739A (ja) 2008-08-28
AR008060A1 (es) 1999-12-09
IL127769A (en) 2006-10-31
RO119862B1 (ro) 2005-05-30
CN1224356A (zh) 1999-07-28
MY121684A (en) 2006-02-28
BR9710130A (pt) 1999-08-10
IL127769A0 (en) 1999-10-28
HUP9903942A3 (en) 2000-07-28
DK0909175T3 (da) 2003-09-29
AU3407397A (en) 1998-01-21
NO986209D0 (no) 1998-12-30
NZ333580A (en) 2000-06-23
DE69722620D1 (de) 2003-07-10
WO1998000152A1 (en) 1998-01-08
SK284490B6 (sk) 2005-05-05
PL330869A1 (en) 1999-06-07
CO4890854A1 (es) 2000-02-28
JP2001504802A (ja) 2001-04-10
AU737664B2 (en) 2001-08-30
SK179998A3 (en) 1999-05-07
EP0909175A1 (en) 1999-04-21
TW491703B (en) 2002-06-21
DE69722620T2 (de) 2004-04-29
CZ433898A3 (cs) 1999-04-14
RU2203085C2 (ru) 2003-04-27
NO986209L (no) 1998-12-30
PL189402B1 (pl) 2005-08-31
EP0909175B1 (en) 2003-06-04
ZA975942B (en) 1998-04-16
JP2010043105A (ja) 2010-02-25
CN1231256C (zh) 2005-12-14
ES2201306T3 (es) 2004-03-16
PT909175E (pt) 2003-10-31
NO323933B1 (no) 2007-07-23
CA2259403A1 (en) 1998-01-08
ID19165A (id) 1998-06-28
ATE241997T1 (de) 2003-06-15

Similar Documents

Publication Publication Date Title
HUP9903942A2 (hu) Nemvizes protikus peptid készítmények
HUP0000589A2 (hu) Vizes peptid készítmények
HUP0002877A2 (hu) Stabil inzulinkészítmények és eljárás előállításukra
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
ATE9475T1 (de) Aminosaeure- und peptid-n-(vinblastinoyl-23)derivate und ihre herstellung.
DK0758248T3 (da) Formuleringer til faktor IX
AU1750097A (en) Highly concentrated, lyophilized, and liquid factor ix formulations
TR199701071T2 (xx) Aktif madde ula�t�rmaya mahsus bile�ikler ve terkipler.
DE60028037D1 (de) LANGFRISTIG STABILISIERTE G-CSF PRäPARATE
HUP0101708A2 (hu) 1,2-Hexándiolt tartalmazó izzadásgátló készítmények
DE69620877D1 (de) Arzneimittelformulierungen für il-12
PT877602E (pt) Processo para o fabrico de composicoes de surfactantes pulmonares em po
BR0208210A (pt) Preparação de insulina pobre em zinco e isenta de zinco com estabilidade aperfeiçoada
CA2069153A1 (en) Pharmaceutical composition
DK0951473T3 (da) Cyclosporinderivat, fremstilling af dette og farmaceutiske præparater indeholdende dette
GB1230472A (hu)
DE69307977D1 (de) Stabilisierte Derivate von Vitamin D2 und D3 enthaltende pharmazeutische Zusammensetzungen
ATE177757T1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
KR860005636A (ko) 활성성분으로 스페르구알린(Spergualin)을 함유하는 주사제 조성물과 그 제조방법.
KR890700125A (ko) 신규 벤즈이미다졸 유도체, 그 제조방법 및 이 화합물을 함유하는 제약 조성물
HUP0002049A2 (hu) Tumornövekedés megakadályozására szolgáló eljárás izoprenoidok és sztatinok kombinációk alkalmazásával
FR2757857B1 (fr) Diselenures et selenosulfures aromatiques, leur preparation et leurs utilisations, notamment therapeutiques
HUP0001850A2 (hu) Jódpropinil-butil-karbamátot és fenoxietanolt tartalmazó tartósítószer
CA2359491A1 (en) Mixture of plant treatment compositions with waxes, their preparation, and their use
ATE311403T1 (de) Derivate des streptogramins, ihre herstellung und sie enthaltende zubereitungen

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees